Has entrectinib entered China?

Entrectinib (Entrectinib) has entered China. This drug is a targeted anti-cancer drug developed by Roche Pharmaceuticals. Its Chinese trade name is Luo Shengquan and its English trade name is ROZLYTREK. Entrectinib is a tyrosine kinase inhibitor (TKI) with central nervous system activity that blocks ROS1 and NTRK kinase activity, leading to the death of cancer cells with ROS1 or NTRK gene fusions. At the same time, it can cross the blood-brain barrier and is the only TRK inhibitor clinically proven to be effective against primary and metastatic brain diseases without adverse off-target activity.

Enrectinib has experienced multiple important milestones in China. In July 2022, entrectinib was first approved in China for the treatment of patients 12 years and older with NTRK fusion-positive solid tumors (cancer growths) who have a genetic abnormality called NTRK gene fusion. Entrectinib is used in patients whose tumor has spread nearby or to other parts of the body (metastatic cancer) or in whom surgery to remove the tumor could cause serious harm. This product should only be used if the patient has not previously been treated with a drug that has the same efficacy as entrectinib and other treatments are not suitable.

Enrectinib contains the active ingrediententrectinib is a cancer drug. In August of the same year, its second indication was also approved for the treatment of adults with advanced ROS1-positive non-small cell lung cancer, which has a genetic abnormality called ROS1 gene fusion. This drug should only be used if the patient has not previously been treated with drugs that block ROS1.